OPRD1 and Alzheimer disease: Importantly, neither activation of DOR in vitro nor blockage of DOR in vivo affected the processing of Notch, N-cadherin, or APLP-1 by either BACE1 or γ-secretase, thus providing direct evidence that antagonism of DOR specifically blocks the amyloidogenic pathway and efficaciously prevents AD progression in mice (Teng et al., 2010).